Abstract: A device for monitoring the spatial and temporal dynamics of thrombin that includes a temperature-controlled sealed chamber with a transparent window and a light trap, the chamber being filled with a fluid medium and designed to accommodate a cuvette containing a test sample of blood plasma, and a coagulation activating insert placed into the cuvette, at least one illumination source and at least one first irradiation source and at least one second irradiation source capable of exciting a fluorescence signal of a special marker that forms in the sample during cleavage of a fluorogenic substrate, a camera, a pressure adjustment element capable of maintaining a pressure inside the chamber, the at least one first irradiation source provides irradiation of the sample in a direction perpendicular to the cuvette, and the at least one second irradiation source provides irradiation of the sample at an angle to the cuvette.

Abstract: The device for monitoring the spatial and temporal dynamics of thrombin that includes a temperature-controlled sealed chamber with a transparent window and a light trap, said chamber being filled with a fluid medium and designed to be capable of accommodating a cuvette containing a test sample of blood plasma, and into which a coagulation activating insert is placed, the latter having a substance which initiates the coagulation process applied to the butt end thereof, at least one means of illumination of the sample designed to be capable of receiving the light scattering signal from the sample and at least one first means of irradiation designed to be capable of exciting the fluorescence signal of a special marker that forms in the sample during the cleavage of a fluorogenic substrate previously added to the sample by one of the proteolytic enzymes of the coagulation system, a means of optical photo/video registration of light scattering/irradiation from the sample, a means for adjustment of pressure in the

Abstract: The present invention relates to medicine, hematology, biotechnology and fundamental biological research; it can be used for diagnostic and research purposes when studying blood coagulation. One of the aspects of the invention is a polypeptide for selective inhibition of contact activation factor XIIa in a sample of blood or plasma, which comprises the sequence of infestin-4 MutB (SEQ ID NO: 1), where this sequence can have modifications outside the area of the inhibitory loop. Another aspect of the invention is a method of studying coagulation in the test sample, which includes bringing the sample into contact with this polypeptide, bringing a coagulation activator into contact with the sample, and measuring the coagulation parameters. Yet another aspect of the invention is a method of blood anticoagulation by this polypeptide for collection purposes and in order to increase the storage time of the sample.

Abstract: The invention relates to the field of medicine and biology. A device for monitoring of spatial coagulation of blood and its uses for diagnostic and research purposes is described. The device includes a thermostatically controlled chamber, at least one means of illumination, a means of recording connected to the thermostatically controlled chamber. The thermostatically controlled chamber includes a cuvette to place a sample of a test medium, a light trap, and is filled with a substance suitable for temperature regulation. The light trap is formed by geometry of the inner surfaces of the thermostatically controlled chamber.

Abstract: The invention relates to the field of biotechnology. The method for determining the spatial and temporal distribution of the activity of a proteolytic enzyme in an in vitro heterogeneous system, such as blood or blood plasma, involves the introduction of a luminescent, fluorogenic or chromogenic substrate into a sample with the subsequent release of a detectable tag as the proteolytic enzyme cleaves the substrate, and the recording of the optical characteristics of the sample, which makes it possible to assess the spatial and temporal distribution of the activity of the enzyme. The device for the implementation of the above method comprises an in vitro system, a means for illuminating the sample, a recording means and a control means. A method for diagnosing homeostatic imbalances according to a change in the spatial and temporal distribution of the activity of a proteolytic enzyme in a blood sample is also proposed.

Abstract: The present invention relates to medicine, and specifically to hematology, and can be used in particular for diagnostic and research purposes when determining coagulation characteristics of blood and its components, and also in biotechnology and fundamental biological research. One of the aspects of the present invention is a polypeptide for inhibition of contact activation in a sample of blood or its product to be tested, which comprises the sequence of an infestin-4 mutant MutB (SEQ ID NO: 1) and which substantially corresponds thereto, where said sequence can have modifications outside the area of the inhibitory loop which significantly maintain the activity of the said polypeptide, which acts as a high-selectivity fXIIa inhibitor, the selectivity of which is higher than that of native infestin-4 and Mut15, or the activity of which is higher than that of native infestin-4 and Mut15.

Abstract: The invention relates to the field of medicine and biology. A device for monitoring of spatial coagulation of blood and its uses for diagnostic and research purposes is described. The device includes a thermostatically controlled chamber, at least one means of illumination, a means of recording connected to the thermostatically controlled chamber. The thermostatically controlled chamber includes a cuvette to place a sample of a test medium, a light trap, and is filled with a substance suitable for temperature regulation. The light trap is formed by geometry of the inner surfaces of the thermostatically controlled chamber.

Abstract: The invention relates to the field of biotechnology. The method for determining the spatial and temporal distribution of the activity of a proteolytic enzyme in an in vitro heterogeneous system, such as blood or blood plasma, involves the introduction of a luminescent, fluorogenic or chromogenic substrate into a sample with the subsequent release of a detectable tag as the proteolytic enzyme cleaves the substrate, and the recording of the optical characteristics of the sample, which makes it possible to assess the spatial and temporal distribution of the activity of the enzyme. The device for the implementation of the above method comprises an in vitro system, a means for illuminating the sample, a recording means and a control means. A method for diagnosing homeostatic imbalances according to a change in the spatial and temporal distribution of the activity of a proteolytic enzyme in a blood sample is also proposed.

Abstract: This invention relates to new chemical compounds, application of these compounds as anticoagulants, pharmaceutical compositions, and plasma-substituting solutions on their basis, and can be used for treating thromboembolic complications of diseases such as myocardial infarction, stroke, and thrombosis of deep veins or a pulmonary artery; and for preventing hypercoagulation conditions in consequence of injuries, surgeries, sepsis, various obstetric pathologies, in disaster medicine, resuscitation, and so on.

Abstract: This invention relates to new chemical compounds, application of these compounds as anticoagulants, pharmaceutical compositions, and plasma-substituting solutions on their basis, and can be used for treating thromboembolic complications of diseases such as myocardial infarction, stroke, and thrombosis of deep veins or a pulmonary artery; and for preventing hypercoagulation conditions in consequence of injuries, surgeries, sepsis, various obstetric pathologies, in disaster medicine, resuscitation, and so on.

Abstract: This invention relates to new chemical compounds, application of these compound as thrombin inhibitors, and pharmaceutical compositions based on them, and can be used to treat and prevent thrombin-dependent thromboembolic events, and in research.